The Wall Street Journal is reporting that the FDA is laying the ground work for a quick review of omicron-targeted vaccines and drugs, if needed.
Dr. Kavita Patel, former White House policy director and fellow at the Brookings Institution, breaks down Pfizer's latest FDA application for its Covid-19 booster.